What changed in Iqvia Holdings Inc.'s latest annual report
In the year ended 31 Dec 2025, Iqvia Holdings Inc.'s revenue rose 5.9% to USD 16.31bn, from USD 15.40bn; net income fell 0.9% to USD 1.36bn, from USD 1.37bn; cash and cash equivalents rose 16.3% to USD 1.98bn, from USD 1.70bn.
Year ended 31 Dec 2025. Source: 10-K filed 17 Feb 2026, read it on SEC EDGAR.
USD 15.40bn to USD 16.31bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 15.40bn | 16.31bn | Up 5.9% |
| Net income | 1.37bn | 1.36bn | Down 0.9% |
| Total assets | 26.90bn | 29.94bn | Up 11.3% |
| Total liabilities | 20.83bn | 23.31bn | Up 11.9% |
| Long-term debt | 12.84bn | 13.88bn | Up 8.1% |
| Cash and cash equivalents | 1.70bn | 1.98bn | Up 16.3% |
| Shareholders' equity | 6.07bn | 6.50bn | Up 7.2% |
Questions people ask
Did Iqvia Holdings Inc.'s revenue grow last year?
Revenue grew 5.9%, from USD 15.40bn to USD 16.31bn in the year ended 31 Dec 2025.
Is Iqvia Holdings Inc. profitable?
Yes. Net income was USD 1.36bn in the year ended 31 Dec 2025. The year before: USD 1.37bn.
How much cash and debt does Iqvia Holdings Inc. have?
At its latest year end (31 Dec 2025), Iqvia Holdings Inc. reported cash and cash equivalents of USD 1.98bn and long-term debt of USD 13.88bn.
Where do these numbers come from?
From Iqvia Holdings Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Iqvia Holdings Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Services-Commercial Physical & Biological Research companies
- Incyte CorporationNet income up 3845%
- Medpace Holdings, Inc.Shareholders' equity down 44.4%
- Charles River Laboratories International, Inc.Cash and cash equivalents up 9.8%
- ICON plcNet income down 69%